SUZHOU, China and ROCKVILLE, MD., U.S., Apr. 21, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the company’s three apoptosis-targeted drug candidates have been selected for presentations at the Read More ›

SUZHOU, China and ROCKVILLE, Md., Apr. 12, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented the preclinical results of five of the company’s novel drug candidates at the American Association for Cancer Research (AACR) Annual Meeting Read More ›

SUZHOU, China and ROCKVILLE, Md., Apr. 2, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company’s Board of Directors as an independent non-executive director, Read More ›

SUZHOU, China and ROCKVILLE, Md., U.S., Mar. 31, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2020, during which the company continued its rapid growth, despite the enormous challenges posed Read More ›

SUZHOU, China and ROCKVILLE, MD., the United States, Mar. 24, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has recommended the novel candidate drug olverembatinib (HQP1351) of Guangzhou Read More ›

SUZHOU, China and ROCKVILLE, Md., Mar. 10, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company’s five novel drug candidates have been selected for presentations at the American Read More ›

SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released the results from a preclinical study of APG-115, a novel MDM2-p53 inhibitor being developed by Ascentage Pharma, Read More ›

SUZHOU, China and ROCKVILLE, Md., Jan. 28, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company’s novel Bcl-2 inhibitor, Read More ›

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company’s novel Bcl-2 inhibitor, APG-2575, for the treatment of Read More ›

SUZHOU, China and ROCKVILLE, Md., Dec. 28, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program (the “Hong Kong Stock Connect”). This was officially announced by the Shenzhen Stock Read More ›